Neither UTMB nor Moderna has confirmed the nature of the project included in the announcement, or how much funding is being lost.

The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses

This includes terminating awards and contracts with pharmaceutical companies and universities and canceling 22 investment projects worth nearly $500 million. While some final-stage contracts will be allowed to be completed, no new mRNA-based projects will be initiated, the HHS said.